Schenkein David P's Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Nov 13, 2024
- Accession no.
- 0001714899-24-000219
- Filed
- Nov 13, 2024
- Trade date
- Nov 11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.93M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schenkein David PCIK 0001578200 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Common Stock | MOption exerciseAcquired | +47,165 | $18.00 | +$848,970 | 68,661 | Direct | |
| Nov 11, 2024 | Common Stock | SSaleDisposed | −27,129 | $32.09 | −$870,569.61 | 41,532 | Direct | |
| Nov 11, 2024 | Common Stock | SSaleDisposed | −32,312 | $32.87 | −$1,062,095.44 | 9,220 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Common Stock | MOption exerciseDisposed | −47,165 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.